16 September 2024
ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies
ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.
27 August 2024
ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant
29 May 2024
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing
The G-Rex® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the material resources and services needed to implement or optimize a highly efficient G-Rex® based cell manufacturing platform.
4 October 2023
CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibility
The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo® and Cue® cell processing systems.
11 May 2023
Cellular Origins Partners With ScaleReady to Simplify, Standardize, and Automate Cell Therapy Manufacturing
Partnership aims to integrate ScaleReady’s CGT manufacturing workflow with Cellular Origins’ robotic technology
Initially focussed on automation of ScaleReady’s G-Rex platform
1 March 2023
Bio-Techne Announces Investment in Wilson Wolf
Bio-Techne Corporation announced Wilson Wolf Manufacturing has met the trailing 12-month earnings before interest, taxes, depreciation, and amortization (EBITDA) target...
26 April 2022
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the...
14 December 2021
Bio-Techne Announces Future Wilson Wolf Purchase Agreement
Bio-Techne announced it has entered into a purchase option agreement with Wilson Wolf Corporation, solidifying resources and support for ScaleReady...
10 November 2021
ScaleReady Launches Second Generation of Wilson Wolf G-Rex Product
The second generation G-Rex500M-CS improves on the materials and ergonomics of the original G-Rex while retaining the same cell expansion...
3 November 2021
Bio-Techne Releases First GMP-grade Cytokines from New GMP Facility
ScaleReady sources Bio-Techne cytokines because of their commitment to supplying the entire cell and gene therapy industry with GMP-grade, animal...
2 June 2021
ScaleReady hosts ISCT Symposium on Intelligent Scale-up
ScaleReady recruited a prestigious panel of cell therapy manufacturing experts to discuss their experiences and strategies for commercial scale up...
6 January 2021
ScaleReady Launches
ScaleReady launches with the mission to make cell and gene therapy manufacturing practical and viable. Through a partnership between Bio-Techne,...